Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06399172
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
Sponsor: OncoSil Medical Limited
View on ClinicalTrials.gov
Summary
The OSPRItaly Patient Registry has been developed to assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.
Official title: OncoSil Pancreatic Cancer Post-marketing Clinical Registry Italy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2024-05-30
Completion Date
2029-10-30
Last Updated
2024-05-03
Healthy Volunteers
No
Interventions
DEVICE
OncoSil
Intra-tumoural implantation